<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:chebi fb="1" ids="24261">Glucocorticoids</z:chebi> and interleukin 10 (IL-10) prevent macrophage activation </plain></SENT>
<SENT sid="1" pm="."><plain>In murine lymphocytes, <z:chebi fb="1" ids="24261">glucocorticoids</z:chebi> induce expression of <z:chebi fb="1" ids="24261">glucocorticoid</z:chebi>-induced leucine zipper (GILZ), which prevents the nuclear factor kappaB (NF-kappaB)-mediated activation of transcription </plain></SENT>
<SENT sid="2" pm="."><plain>We investigated whether GILZ could account for the deactivation of macrophages by <z:chebi fb="1" ids="24261">glucocorticoids</z:chebi> and IL-10 </plain></SENT>
<SENT sid="3" pm="."><plain>We found that GILZ was constitutively produced by macrophages in nonlymphoid tissues of humans and mice </plain></SENT>
<SENT sid="4" pm="."><plain><z:chebi fb="1" ids="24261">Glucocorticoids</z:chebi> and IL-10 stimulated the production of GILZ by macrophages both in vitro and in vivo </plain></SENT>
<SENT sid="5" pm="."><plain>Transfection of the macrophagelike cell line <z:chebi fb="0" ids="46941">THP</z:chebi>-1 with the GILZ gene inhibited the expression of CD80 and CD86 and the production of the proinflammatory chemokines regulated on activation <z:mpath ids='MPATH_458'>normal</z:mpath> T-cell expressed and secreted (CCL5) and macrophage inflammatory protein 1alpha (CCL3) </plain></SENT>
<SENT sid="6" pm="."><plain>It also prevented toll-like receptor 2 production induced by <z:chebi fb="0" ids="16412">lipopolysaccharide</z:chebi>, interferongamma, or an anti-CD40 mAb, as well as NF-kappaB function </plain></SENT>
<SENT sid="7" pm="."><plain>In <z:chebi fb="0" ids="46941">THP</z:chebi>-1 cells treated with <z:chebi fb="1" ids="24261">glucocorticoids</z:chebi> or IL-10, GILZ was associated with the p65 subunit of NF-kappaB </plain></SENT>
<SENT sid="8" pm="."><plain>Activated macrophages in the granulomas of patients with <z:e sem="disease" ids="C0010346" disease_type="Disease or Syndrome" abbrv="">Crohn disease</z:e> or <z:e sem="disease" ids="C0041296" disease_type="Disease or Syndrome" abbrv="tb|tbc">tuberculosis</z:e> do not produce GILZ </plain></SENT>
<SENT sid="9" pm="."><plain>In contrast, GILZ production persists in <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e>-infiltrating macrophages in Burkitt <z:hpo ids='HP_0002665'>lymphomas</z:hpo> </plain></SENT>
<SENT sid="10" pm="."><plain>Therefore, GILZ appears to play a key role in the anti-inflammatory and immunosuppressive effects of <z:chebi fb="1" ids="24261">glucocorticoids</z:chebi> and IL-10 </plain></SENT>
<SENT sid="11" pm="."><plain><z:chebi fb="1" ids="24261">Glucocorticoid</z:chebi> treatment stimulates GILZ production, reproducing an effect of IL-10, a natural <z:chebi fb="1" ids="35472">anti-inflammatory agent</z:chebi> </plain></SENT>
<SENT sid="12" pm="."><plain>The development of <z:mp ids='MP_0002534'>delayed-type hypersensitivity</z:mp> reactions is associated with the down-regulation of GILZ gene expression within lesions </plain></SENT>
<SENT sid="13" pm="."><plain>In contrast, the persistence of GILZ gene expression in macrophages infiltrating Burkitt <z:hpo ids='HP_0002665'>lymphomas</z:hpo> may contribute to the failure of the immune system to reject the <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> </plain></SENT>
</text></document>